Cancer Drug Hand-Foot Syndrome Risks Mapped in Huge FDA Analysis

A large FDA adverse event dataset analysis identified 427 drugs linked to hand-foot syndrome in cancer patients, highlighting protein kinase inhibitors and antimetabolites as primary contributors, with most cases occurring within 90 days of treatment start. The study suggests early patient education and monitoring during treatment initiation to prevent severe symptoms.

This Wire brief sits within Fusion42's coverage of Drug Discovery.